A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder

References

• Ayano G, Demelash S, Gizachew Y, et al. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: an umbrella review of meta-analyses. J Affect Disord. 2023;339:860–866. doi: 10.1016/j.jad.2023.07.071
   PubMed Web of Science ®Google Scholar
• Still GF. Nervous children. King’s Coll Hosp Rep. 1901;7:41–51.
   Google Scholar
• Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94(4):577–585.
   Google Scholar
• Bradley C, Bowen M. Amphetamine (Benzedrine) therapy of children’s behavior disorders. Am J Ortho. 1940;11(1):92–103. doi: 10.1111/j.1939-0025.1941.tb05781.x
   Google Scholar
• Cortese S, Ropper AH. Pharmacologic treatment of attention deficit–hyperactivity disorder. N Engl J Med. 2020 Sep 10;383(11):1050–1056. PMID: 32905677. doi: 10.1056/NEJMra1917069
   PubMed Web of Science ®Google Scholar
• Chen KK, Schmidt CF. The action of ephedrine, an alkaloid from Ma Huang. Proceedings of the Society for Experimental Biology and Medicine; Bloomsbury, London, England. 1923;21. p. 351–354.
   Google Scholar
• Chen KK, Schmidt CF. The action and clinical use of ephedrine. J Am Med Assoc. 1926;87(11):836–842. doi: 10.1001/jama.1926.02680110036011
   Google Scholar
• Rasmussen N. Amphetamine-type stimulants: the early history of their medical and non-medical uses. Int Rev Neurobiol. 2015;120:9–25.
   PubMed Web of Science ®Google Scholar
• Rasmussen N. On speed: the many lives of amphetamine. (NY): New York University Press; 2008.
   Google Scholar
• The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–1086. doi: 10.1001/archpsyc.56.12.1073
   PubMed Web of Science ®Google Scholar
• Lindemann L, Meyer CA, Jeanneau K, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2008;324(3):948–956.
   PubMed Web of Science ®Google Scholar
• Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 2011;116(2):164–176. doi: 10.1111/j.1471-4159.2010.07109.x
   PubMed Web of Science ®Google Scholar
• Lewin AH, Miller GM, Gilmour B. Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class. Bioorg Med Chem. 2011;19(23):7044–7048. doi: 10.1016/j.bmc.2011.10.007
   PubMed Web of Science ®Google Scholar
• McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(6):673–683. doi: 10.1097/01.CHI.0000046863.56865.FE
   PubMed Web of Science ®Google Scholar
• Swanson JM. Long-acting stimulants: development and dosing. Can Child Adolesc Psychiatr Rev. 2005;14(Supplement 1):4–9.
   PubMedGoogle Scholar
• ADDERALL XR – dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release. DailyMed. National Library of Medicine. 2023 [cited 2023 Nov 6]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0
   Google Scholar
• Dextroamphetamine. DrugBank Online. 2023 [cited 2023 Nov 6]. Available from: https://go.drugbank.com/drugs/DB01576
   Google Scholar
• Elia J. Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry. 2004;2(1):27–35.
   Google Scholar
• Ambrosini PJ, Sallee FR. An open-label trial of adderall-XR: safety and efficacy assessments. In: Presented at the 2002 American academy of child & adolescent psychiatry. San Francisco (CA); 2002.
   Google Scholar
• Takeda Pharma. Mydayis (mixed salts of a single-entity amphetamine product): highlights of prescribing information. 2023. Available from: http://pi.shirecontent.com/PI/PDFs/Mydayis_USA_ENG.pdf
   Google Scholar
• Cutler AJ, Childress AC, Pardo A, et al. Randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of amphetamine extended-release tablets in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2022;83(5):22m14438. 2. Data on file. Tris Pharma, Inc; 2020. 3. Pardo A, Kando JC, King TR, Rafla E, Herman BK. CNS Spectr. 2020;25(6):774-781. doi: 10.4088/JCP.22m14438
   PubMed Web of Science ®Google Scholar
• Tris Pharma. Dyanavel XR. 2023. [cited 2023 Nov 6]. Available from: https://www.trisadhd.com/dyanavel-xr-tablet/study-results/
   Google Scholar
• Sikes C, Stark JG, McMahen R, et al. Pharmacokinetics of a new amphetamine extended-release oral liquid suspension under fasted and fed conditions in healthy adults: a randomized, open-label, single-dose, 3-treatment study. Clin Ther. 2017;39(12):2389–2398. doi: 10.1016/j.clinthera.2017.10.018
   PubMed Web of Science ®Google Scholar
• Steingard R, Taskiran S, Connor DF, et al. New formulations of stimulants: an update for Clinicians [published correction appears in J child adolesc psychopharmacol. 2020 Apr;30(3): 202]. J Child Adolesc Psychopharmacol. 2019;29(5):324–339. doi: 10.1089/cap.2019.0043
   PubMed Web of Science ®Google Scholar
• Amedra Pharma. (2013). Dexedrine: highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdf
   Google Scholar
• Elia J. Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry. 2005;2(1):27–35.
   PubMedGoogle Scholar
• Takeda Pharma. (2021). Vyvanse: highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021977s046,208510s003lbl.pdf
   Google Scholar
• For how long did vyvanse (lisdexamfetamine dimesylate) help improve attention in adults? Takeda. 2023 [cited 2023 Nov 6]. Available from: https://www.vyvanse.com/adhd-adult-medication
   Google Scholar
• Noven Therapeutics. Xelstrym: highlights of prescribing information. 2022. Available from: https://www.xelstrym.com/pdfs/prescribing-information.pdf
   Google Scholar
• Cutler AJ, Suzuki K, Starling B, et al. Efficacy and safety of dextroamphetamine transdermal system for the treatment of attention-Deficit/Hyperactivity disorder in children and adolescents: results from a pivotal phase 2 study. J Child Adolesc Psychopharmacol. 2022;32(2):89–97. doi: 10.1089/cap.2021.0107
   PubMed Web of Science ®Google Scholar
• MEDICE Arzneimittel Pütter GmbH & Co. KG. Attentin: Highlights of Prescribing Information; 2023. Availble from: https://docetp.mpa.se/LMF/Attentin%205%20mg%20tablet%20ENG%20SmPC_09001bee807a3d23.pdf
   Google Scholar
• U-V Sandersleben H, Dangel O, Fischer R, et al. Effectiveness and safety of dexamphetamine sulfate (Attentin®) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study. Scand J Child Adolesc Psychiatr Psychol. 2021 Apr 23;9(1): 73–86. PMID: 33928056; PMCID: PMC8077785. doi: 10.21307/sjcapp-2021-009
   PubMedGoogle Scholar
• James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1268–1276. doi: 10.1097/00004583-200111000-00006
   PubMed Web of Science ®Google Scholar
• Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(2 Pt 1):258–266.
   PubMed Web of Science ®Google Scholar
• McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(6):530–538. doi: 10.1097/01.chi.0000157550.94702.a2
   PubMed Web of Science ®Google Scholar
• Ambrosini PJ, Sallee FR, Lopez FA, et al. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD. Curr Med Res Opin. 2006;22(2):427–440. doi: 10.1185/030079906X80639
   PubMed Web of Science ®Google Scholar
• Wilson HK, Cox DJ, Merkel RL, et al. Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2006;21(8):797–807. doi: 10.1016/j.acn.2006.06.016
   PubMed Web of Science ®Google Scholar
• Biederman J, Spencer TJ, Wilens TE, et al. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):16–25. doi: 10.1017/S1092852900002406
   PubMed Web of Science ®Google Scholar
• Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1):275–289. doi: 10.1177/1087054705281121
   PubMedGoogle Scholar
• Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–279. doi: 10.1016/j.clinthera.2006.02.011
   PubMed Web of Science ®Google Scholar
• Biederman J, Wigal SB, Spencer TJ, et al. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther. 2006;28(2):280–293. doi: 10.1016/j.clinthera.2006.02.008
   PubMed Web of Science ®Google Scholar
• Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–639. doi: 10.1017/S1092852900013687
   PubMed Web of Science ®Google Scholar
• Faraone SV, Wigal SB, Hodgkins P. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord. 2007;11(1):74–82. doi: 10.1177/1087054706292196
   PubMedGoogle Scholar
• Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970–976. doi: 10.1016/j.biopsych.2007.04.015
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437–1448. doi: 10.4088/JCP.v69n0911
   PubMed Web of Science ®Google Scholar
• Mikami AY, Cox DJ, Davis MT, et al. Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder. J Clin Psychol Med Settings. 2009;16(3):233–242. doi: 10.1007/s10880-009-9165-8
   PubMed Web of Science ®Google Scholar
• Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581–588. doi: 10.1089/cap.2011.0018
   PubMed Web of Science ®Google Scholar
• Wigal T, Childress A, Frick G, et al. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. Postgrad Med. 2018;130(1):111–121. doi: 10.1080/00325481.2018.1389227
   PubMed Web of Science ®Google Scholar
• Wigal S, Lopez F, Frick G, et al. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD. Postgrad Med. 2019;131(3):212–224. doi: 10.1080/00325481.2019.1574402
   PubMed Web of Science ®Google Scholar
• Adler LA, Robertson B, Chen J, et al. Post hoc responder and remission analyses from two studies of SHP465 mixed amphetamine salts extended-release among adults with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30(7):427–438. doi: 10.1089/cap.2020.0012
   PubMed Web of Science ®Google Scholar
• Mattingly G, Arnold V, Yan B, et al. A phase 3, randomized double-blind study of the efficacy and safety of low-dose SHP465 mixed amphetamine salts extended-release in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30(9):549–557. doi: 10.1089/cap.2020.0005
   PubMed Web of Science ®Google Scholar
• Frick G, Yan B, Adler LA. Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial. J Atten Disord. 2020;24(3):402–413. doi: 10.1177/1087054717696771
   PubMed Web of Science ®Google Scholar
• Brown TE, Chen J, Robertson B. Improved executive function in adults diagnosed with attention-deficit/Hyperactivity disorder as measured by the brown attention-deficit disorder scale following treatment with SHP465 mixed amphetamine salts extended-release: post hoc analyses from 2 randomized, placebo-controlled studies. J Atten Disord. 2022;26(2):256–266. doi: 10.1177/1087054720961819
   PubMed Web of Science ®Google Scholar
• Gabriel A. The mixed amphetamine salt extended release (adderall XR, max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study. Atten Defic Hyperact Disord. 2010;2(2):87–92. doi: 10.1007/s12402-010-0025-z
   PubMedGoogle Scholar
• Levin FR, Mariani JJ, Specker S, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/Hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(6):593–602. doi: 10.1001/jamapsychiatry.2015.41
   PubMed Web of Science ®Google Scholar
• Notzon DP, Mariani JJ, Pavlicova M, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. Am J Addict. 2016;25(8):666–672. doi: 10.1111/ajad.12467
   PubMed Web of Science ®Google Scholar
• Blevins D, Choi CJ, Pavlicova M, et al. Impulsiveness as a moderator of amphetamine treatment response for cocaine use disorder among ADHD patients. Drug Alcohol Depend. 2020;213:108082. doi: 10.1016/j.drugalcdep.2020.108082
   PubMed Web of Science ®Google Scholar
• Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118(3):e704–e710. doi: 10.1542/peds.2005-2947
   PubMed Web of Science ®Google Scholar
• Kay GG, Michaels MA, Pakull B. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. J Atten Disord. 2009;12(4):316–329. doi: 10.1177/1087054708322986
   PubMed Web of Science ®Google Scholar
• Sallee FR, Ambrosini PJ, Lopez FA. et al. Health-related quality of life and treatment satisfaction and preference in a community assessment study of extended-release mixed amphetamine salts for children with attention-deficit/hyperactivity disorder. J Outcomes Res. 2004;2:7–49.
   Google Scholar
• Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the quality of life, effectiveness, safety, and tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):26–34. doi: 10.1017/S1092852900002418
   PubMed Web of Science ®Google Scholar
• Weiss MD, Gibbins C, Goodman DW, et al. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(4):381–390. doi: 10.4088/JCP.08m04709pur
   PubMed Web of Science ®Google Scholar
• Neos Therapeutics. Adzenys: highlights of prescribing information. Denver, CO: Adzenys XR-ODT Prescribing Information (aytubio.com); 2023. https://aytubio.com/downloads/Adzenys/Adzenys_PI.pdf
   Google Scholar
• Therapeutic Goods (Poisons Standard – October 2023). Instrument 2023. Australia: Federal Register of Legislation. 2023 [cited 2023 Oct 30]. Available from: https://www.legislation.gov.au/Details/F2023L01294
   Google Scholar
• Prescription Stimulants. Canadian Centre on Substance Use and addiction. 2022 [cited 2023 Oct 30]. Available from: https://www.ccsa.ca/sites/default/files/2022-05/CCSA-Canadian-Drug-Summary-Prescription-Stimulants-2022-en.pdf
   Google Scholar
• Dextroamphetamine-Amphetamine. StatPearls. 2023 [cited 2023 Oct 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507808/
   Google Scholar
• Dexamed and associated names. European Commission final decision. Amsterdam (NL): European Medicines Agency. 2014 [cited 2023 Oct 30]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/dexamed-associated-names#:~:text=Dexamfetamine%20belongs%20to%20a%20group,helping%20to%20reduce%20impulsive%20behaviour
   Google Scholar
• European Medicines Agency decision of 17 March 2022 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine (dimseylate), Elvanse and associated names). Amsterdam (NL): European Medicines Agency 2022 [cited 2023 Oct 30] Available from: https://www.ema.europa.eu/en/documents/pip-decision/p/0097/2022-ema-decision-17-march-2022-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
   Google Scholar
• Frequently Asked Medications. Japan Healthcare Info, 2019 [cited 2023 Oct 30]. Available from: https://japanhealthinfo.com/frequently-asked-medications/
   Google Scholar